GLP-1, GIP & Triple Agonist Research Hub
Complete scientific monographs, 16 to 24-week titration schedules, deterministic reconstitution calculators, and clinical trial outcome comparisons for Semaglutide, Tirzepatide, and Retatrutide.
Semaglutide
Selective Long-Acting GLP-1 Receptor Agonist
Mechanism of Action
Mimics endogenous GLP-1 hormone to suppress glucagon release, delay gastric emptying, and regulate central appetite pathways.
Tirzepatide
Dual-Action GIP and GLP-1 Receptor Agonist
Mechanism of Action
Simultaneously activates GIP and GLP-1 receptors, enhancing insulin secretion and fat metabolism synergistically.
Retatrutide
Next-Gen Triple Hormone Receptor Agonist (Tri-Agonist)
Mechanism of Action
Uniquely targets GLP-1, GIP, and Glucagon receptors to accelerate lipolysis, increase energy expenditure, and regulate satiety.
GLP-1 Titration & Escalation Schedule Generator
Select any GLP-1 compound below to view week-by-week escalation steps, dosage thresholds, and recommended administration protocols.
Dose Escalation Schedule Generator
Standard 16-week ramp-up protocol based on clinical study paradigms.
Visual Dose Ramp Schedule (Semaglutide)
| Timeline | Dose (mg) | Frequency | Protocol Phase |
|---|---|---|---|
| Weeks 1 - 4 | 0.25 mg | Once weekly | Initial initiation phase |
| Weeks 5 - 8 | 0.5 mg | Once weekly | First step-up |
| Weeks 9 - 12 | 1 mg | Once weekly | Intermediate dose |
| Weeks 13 - 16 | 1.7 mg | Once weekly | High intermediate |
| Weeks 17 - 20 | 2.4 mg | Once weekly | Maximum target research dose |
Semaglutide vs. Tirzepatide vs. Retatrutide
Side-by-side scientific comparison of receptor pharmacology, trial weight loss velocity, and dosing guidelines.
| Feature / Metric | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor Targets | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Primary Class | Single Agonist | Dual Agonist | Triple Agonist |
| Plasma Half-Life | ~7 Days | ~5 Days | ~6 Days |
| Peak Clinical Weight Loss | 14.9% | 20.9% | 24.2% |
| Key Clinical Trial | STEP-1 (68 Weeks) | SURMOUNT-1 (72 Weeks) | Phase 2 (48 Weeks) |
| Initiation Dose | 0.25 mg Weekly | 2.5 mg Weekly | 2.0 mg Weekly |
| Maximum Maintenance | 2.4 mg Weekly | 15.0 mg Weekly | 12.0 mg Weekly |
| Regulatory Status | FDA Approved | FDA Approved | Phase 3 Clinical Trial |
Looking for a Licensed GLP-1 Clinic or Telehealth Physician?
Browse our independent nationwide directory of 4,700+ state-licensed medical practices offering GLP-1 weight management, TRT, and peptide consultations in your state.
Frequently Asked Questions
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist that activates two metabolic pathways. Retatrutide is an experimental triple agonist targeting GIP, GLP-1, and Glucagon receptors for maximum metabolic acceleration.
Gradual titration (starting at low doses and stepping up every 4 weeks) allows the gastrointestinal system to adapt to reduced gastric motility, significantly minimizing nausea, cramping, and appetite suppression side effects.
Inject bacteriostatic water (BAC water) slowly along the glass wall of the peptide vial. Gently rotate the vial until completely dissolved. Never shake the vial vigorously. Use our specialized Reconstitution Calculators to get exact U-100 syringe units.
You can use our nationwide Verified Clinic Directory to search for state-licensed medical providers, telehealth physicians, and specialized obesity medicine clinics near you.